Compare Oxford Lane Capital Corp (OXLC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs Sanofi SA — how do they compare? Oxford Lane Capital Corp trades at $8.67 (market cap $835.71M), while Sanofi SA trades at $40.17 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 113.9× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (28.15%). Which is the better fit depends on your goals — on Pluang, investors hold Oxford Lane Capital Corp for 49 Days and Sanofi SA for 94 Days on average.
| OXLC | SNY | |
|---|---|---|
Market Cap | $835.71M | $95.18B |
Volume | 1,125,263 | 2,995,646 |
Sector | Financials | Health |
52-Week High | $16.74 | $52.34 |
52-Week Low | $8.15 | $39.51 |
Typical Hold Time | 49 Days | 94 Days |
Enterprise Value | $1.23B | $114.48B |
Dividend Yield | 28.15% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.535, up 0.89% on the day, with a bearish technical signal from moving averages. The stock shows a low P/B of 0.81 and a high net income margin of 100.85% for 2025, but recent earnings misses and a sharp decline in 2026 revenue and net profit to negative figures highlight significant volatility. The company maintains a regular dividend payout of $0.20 monthly, supported by financing activities, but faces challenges from operational cash outflows and negative ROE/ROA.
Outlook is cautious due to earnings instability and bearish technicals, though the dividend yield may attract income seekers. Key risks include sustained operational losses, high interest expenses, and reliance on financing for dividends. Analyst consensus is mixed with 50% buy ratings, indicating divided sentiment on recovery potential amid current headwinds.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
